Maternal thrombophilia and neonatal thrombosis.
In neonates and infants, numerous clinical and environmental conditions lead to elevated thrombin generation and subsequent thrombus formation. Genetic prothrombotic defects (protein C, protein S and antithrombin deficiency, mutations of coagulation factor V and factor II, elevated lipoprotein (a)) have been established as risk factors of thromboembolic events in neonates and infants. The interpretation of the laboratory evaluation relies on age-dependent normal reference values. Because appropriate clinical trials are missing in these age groups, treatment recommendations are adapted from small-scale studies in neonates and infants and from guidelines relating to adult patient protocols. Secondary long-term anticoagulation should be administered on an individual basis.
Heller
Christine
C
Paediatric Haematology/Oncology, University Hospital of Frankfurt, Germany.
Nowak-Göttl
Ulrike
U
D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D011247:Pregnancy; D011296:Prenatal Diagnosis; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications*; D013927:Thrombosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*
D005343:Fibrinolytic Agents